dr. vaishampayan on the potential of tivozanib in advanced rcc
Published 3 years ago • 107 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
1:15
dr. vaishampayan on the safety of tivozanib versus sorafenib in rcc
-
1:41
tivozanib tolerability shows potential advantage for patients with advanced rcc
-
1:24
dr. motzer on the tivo-1 trial with tivozanib in advanced rcc
-
1:17
dr. vaishampayan on axitinib plus pembrolizumab in advanced rcc
-
2:06
dr. rini discusses tivozanib in advanced rcc
-
1:53
baseline tumor size as a prognostic index in patients with cancer receiving targeted agents
-
34:49
adrenal neoplasms
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
0:59
data support use of tivozanib in patients with advanced renal cell carcinoma
-
12:49
the tivo-3 study of tivozanib in metastatic renal cell carcinoma
-
1:28
dr. motzer on the tivo-3 trial examining tivozanib in advanced rcc
-
0:54
dr. vaishampayan on immunotherapy trials in kidney cancer
-
4:18
tivozanib for refractory advanced rcc
-
0:50
dr. pal on the benefit of tivozanib in later-line settings for refractory rcc
-
0:52
dr. pal on the rationale for the tivo-3 trial with tivozanib in advanced rcc
-
10:49
updated appraisal of late-line tivozanib in advanced clear-cell rcc
-
1:44
tivo-3: tivozanib hydrochloride vs sorafenib for refractory advanced rcc
-
1:57
dr. mayer on tivozanib in renal cell carcinoma and breast cancer
-
2:43
adverse effect profile for tivozanib plus sorafenib for relapsed/refractory renal cell carcinoma
-
4:42
asco: tivozanib for metastatic renal cell carcinoma
-
3:53
fortune: tivozanib plus nivolumab for advanced nccrcc